Literature DB >> 19002436

Phosphorylation of phospholamban and troponin I through 5-HT4 receptors in the isolated human atrium.

Ulrich Gergs1, Joachim Neumann, Andreas Simm, Rolf-Edgar Silber, Freerk Ole Remmers, Stephanie Läer.   

Abstract

We studied the mRNA expression and function of 5-hydroxytryptamine (5-HT) receptors as well as their signal transduction in right atrial tissue from patients undergoing cardiac surgery and right ventricular tissue from human donor hearts. In isolated, electrically driven strips from human right atrium, 5-HT exerted concentration-dependent positive inotropic effects (EC(50) value = 0.10 +/- 0.01 microM) and hastened relaxation (positive lusitropic effect). The 5-HT(4) receptor antagonists SB203186 or GR125487 antagonised these effects. 5-HT (2 microM) increased the content of cyclic adenosine monophosphate (cAMP) from 6.86 +/- 1.36 to 19.1 +/- 2.45 pmol/mg protein (n = 6, p < 0.05) but did not alter the tissue content of inositol-1,4,5-trisphosphate (IP(3)). With reverse transcription polymerase chain reaction, mRNAs coding for the 5-HT(4) receptor splice variants 5-HT(4(a)), 5-HT(4(b)) and 5-HT(4(c)) were detected in human right atrium and right ventricle. 5-HT(2A) mRNA only was measurable in human atrium. Expression level of total 5-HT(4) receptor mRNA in the right ventricle amounted to 41% (n = 5-8) of that in the right atrium. 5-HT (2 microM) increased the atrial phosphorylation states of phospholamban to 168% at serine-16 and to 150% at threonine-17 (n = 4; p < 0.05) and of the inhibitory subunit of troponin to 150% (n = 6; p < 0.05). In conclusion, the positive inotropic and lusitropic effects of 5-HT in electrically driven human right atria are mediated via 5-HT(4) receptors. These effects are accompanied by and probably due to an increase in cAMP content and the subsequent elevation of the phosphorylation state of Ca(2+) regulatory proteins.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19002436     DOI: 10.1007/s00210-008-0371-y

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  46 in total

1.  Biochemical mechanism(s) of stunning in conscious dogs.

Authors:  H Lüss; A Meissner; N Rolf; H Van Aken; P Bokník; U Kirchhefer; J Knapp; S Läer; B Linck; I Lüss; F U Müller; J Neumann; W Schmitz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-07       Impact factor: 4.733

2.  Comparison of the densities of 5-HT4 receptors, beta 1- and beta 2-adrenoceptors in human atrium: functional implications.

Authors:  A J Kaumann; J A Lynham; A M Brown
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-04       Impact factor: 3.000

Review 3.  Molecular, pharmacological and functional diversity of 5-HT receptors.

Authors:  Daniel Hoyer; Jason P Hannon; Graeme R Martin
Journal:  Pharmacol Biochem Behav       Date:  2002-04       Impact factor: 3.533

4.  Labelling with [125I]-SB 207710 of a small 5-HT4 receptor population in piglet right atrium: functional relevance.

Authors:  A J Kaumann; J A Lynham; A M Brown
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

5.  Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors.

Authors:  J M Van Nueten; P A Janssen; J Van Beek; R Xhonneux; T J Verbeuren; P M Vanhoutte
Journal:  J Pharmacol Exp Ther       Date:  1981-07       Impact factor: 4.030

6.  Adenosine inhibition of catecholamine-induced increase in force of contraction in guinea-pig atrial and ventricular heart preparations. Evidence against a cyclic AMP- and cyclic GMP-dependent effect.

Authors:  M Böhm; R Brückner; I Hackbarth; B Haubitz; R Linhart; W Meyer; B Schmidt; W Schmitz; H Scholz
Journal:  J Pharmacol Exp Ther       Date:  1984-08       Impact factor: 4.030

7.  Cloning, pharmacological characterisation and tissue distribution of a novel 5-HT4 receptor splice variant, 5-HT4(i).

Authors:  Trond Brattelid; Ane M Kvingedal; Kurt A Krobert; Kjetil W Andressen; Trond Bach; Marit E Hystad; Alberto J Kaumann; Finn Olav Levy
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-04-30       Impact factor: 3.000

Review 8.  International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin).

Authors:  D Hoyer; D E Clarke; J R Fozard; P R Hartig; G R Martin; E J Mylecharane; P R Saxena; P P Humphrey
Journal:  Pharmacol Rev       Date:  1994-06       Impact factor: 25.468

9.  Serotonin increases L-type Ca2+ current and SR Ca2+ content through 5-HT4 receptors in failing rat ventricular cardiomyocytes.

Authors:  Jon Arne Kro Birkeland; Fredrik Swift; Nils Tovsrud; Ulla Enger; Per Kristian Lunde; Eirik Qvigstad; Finn Olav Levy; Ole M Sejersted; Ivar Sjaastad
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-07-27       Impact factor: 4.733

10.  Messenger RNA expression and immunological quantification of phospholamban and SR-Ca(2+)-ATPase in failing and nonfailing human hearts.

Authors:  B Linck; P Bokník; T Eschenhagen; F U Müller; J Neumann; M Nose; L R Jones; W Schmitz; H Scholz
Journal:  Cardiovasc Res       Date:  1996-04       Impact factor: 10.787

View more
  13 in total

1.  Arrhythmias, elicited by catecholamines and serotonin, vanish in human chronic atrial fibrillation.

Authors:  Torsten Christ; Nadiia Rozmaritsa; Andreas Engel; Emanuel Berk; Michael Knaut; Katharina Metzner; Manuel Canteras; Ursula Ravens; Alberto Kaumann
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-14       Impact factor: 11.205

2.  On the presence of serotonin in mammalian cardiomyocytes.

Authors:  Klaus Pönicke; Ulrich Gergs; Igor B Buchwalow; Steffen Hauptmann; Joachim Neumann
Journal:  Mol Cell Biochem       Date:  2012-02-25       Impact factor: 3.396

3.  Influence of phosphodiesterases and cGMP on cAMP generation and on phosphorylation of phospholamban and troponin I by 5-HT4 receptor activation in porcine left atrium.

Authors:  Sabine Weninger; Joris H De Maeyer; Romain A Lefebvre
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-03       Impact factor: 3.000

4.  Cardiovascular effects of cisapride and prucalopride on human 5-HT4 receptors in transgenic mice.

Authors:  Nicolas Keller; Stefan Dhein; Joachim Neumann; Ulrich Gergs
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-06-09       Impact factor: 3.000

5.  Desensitization of the human 5-HT4 receptor in isolated atria of transgenic mice.

Authors:  Ulrich Gergs; Julia Fritsche; Stephanie Fabian; Josepha Christ; Joachim Neumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-07-08       Impact factor: 3.000

6.  Which phosphodiesterase can decrease cardiac effects of 5-HT4 receptor activation in transgenic mice?

Authors:  Joachim Neumann; Benedikt Käufler; Ulrich Gergs
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-04-24       Impact factor: 3.000

7.  Surprises from a cardiac 5-HT₄TG mouse: spontaneous atrial arrhythmias by endogenous 5-HT of atrial origin? Different mechanism of arrhythmias through 5-HT₄ receptors and β-adrenoceptors?

Authors:  Alberto J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-05       Impact factor: 3.000

8.  Human 5-HT₄receptor stimulation in atria of transgenic mice.

Authors:  Ulrich Gergs; Anne Böckler; Henning Ebelt; Steffen Hauptmann; Nicolas Keller; Volker Otto; Klaus Pönicke; Wilhelm Schmitz; Joachim Neumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-01-11       Impact factor: 3.000

9.  Influence of Serotonin 5-HT4 Receptors on Responses to Cardiac Stressors in Transgenic Mouse Models.

Authors:  Ulrich Gergs; Timo Gerigk; Jonas Wittschier; Constanze T Schmidbaur; Clara Röttger; Mareen Mahnkopf; Hanna Edler; Hartmut Wache; Joachim Neumann
Journal:  Biomedicines       Date:  2021-05-18

10.  Phosphodiesterases 2, 3 and 4 can decrease cardiac effects of H2-histamine-receptor activation in isolated atria of transgenic mice.

Authors:  Joachim Neumann; Rafaela Voss; Ulrich Laufs; Christian Werner; Ulrich Gergs
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-02-12       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.